Pregnancy Often Coincided With Fewer Relapses in MOGAD, but Postpartum Risk Stayed Unstable
Pregnancy appears to suppress relapse activity in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in much of the published literature, yet the postpartum period remains less predictable. An updated systematic review pulled together the small and heterogeneous evidence base and separated pregnancies conceived after disease onset from first disease presentations occurring during pregnancy or within 12 months after delivery or pregnancy loss. The signal was directionally consistent across several cohorts: gestation was usually linked to fewer relapses, while the months after delivery showed a more mixed pattern.
A Small Evidence Base Still Shapes Counseling
Nine independent studies, represented in ten reports, formed the evidence base. PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched through 21 July 2026, and design-matched appraisal tools were applied to the included reports. The review used a descriptive quantitative synthesis rather than a formal meta-analysis, a choice driven by the sparse and heterogeneous data. In a disease where counseling decisions often must be made before the literature is mature, that distinction matters because the available cohorts do not yet support a single pooled estimate with confidence.
The authors separated the analysis carefully. Pregnancies that occurred after MOGAD onset were handled apart from first attacks that emerged during the pregnancy-associated window, because the clinical meaning of those scenarios is different. A relapse in a woman with established disease raises questions about treatment interruption, immune shifts, and postpartum rebound. A first demyelinating presentation during pregnancy or shortly after delivery raises a different diagnostic burden entirely, because clinicians must decide whether the pregnancy itself is revealing a predisposition or simply coinciding with the first recognized attack.
Gestation Showed the Clearest Drop in Annualized Relapse Activity
Among the four studies reporting gestational annualized relapse rates, the pregnancy-to-prepregnancy relapse-rate ratio was 0 in three cohorts: Collongues et al., Carra-Dallière et al., and Kim et al. In Hyun et al., the ratio was 0.12, and the decline reached statistical significance. Even without pooled analysis, the pattern is difficult to miss: relapse activity dropped sharply during pregnancy in the available cohorts.
The biological plausibility is strong. Pregnancy shifts immune balance toward tolerance, and diseases with antibody-mediated components can quiet down when inflammatory pressure is dampened. In MOGAD, where relapse biology likely depends on humoral immune activity and inflammatory signaling around the central nervous system, those gestational changes may blunt the pathways that ordinarily drive attack frequency. The clinical consequence is practical at the bedside: a patient who is stable before conception may remain stable through pregnancy more often than previously feared, but that reassurance should not be overextended beyond the gestational period.
Postpartum Risk Moved in a Less Predictable Direction
The 12-month postpartum-to-prepregnancy relapse-rate ratio was below 1 in four of five studies, ranging from 0.33 to 0.69. One study reported a ratio of 1.50, but that estimate came from only five pregnancies. A confidence interval could be derived for just one study, and it was wide. The postpartum literature therefore points in the same general direction as the gestational data, but with less consistency and far more statistical uncertainty.
This is the period where immunologic rebound, sleep deprivation, treatment interruption, and the physiologic stress of delivery can all converge. In demyelinating disease, postpartum worsening often reflects the rapid reversal of pregnancy-associated immune adaptation. The available MOGAD evidence does not establish a uniform postpartum surge, but it does show that the window after delivery cannot be treated as biologically neutral. A patient may sail through pregnancy and still face renewed risk after birth, especially when disease-modifying strategies are paused or delayed.
First Presentations During the Pregnancy-Associated Window Remain Hard to Quantify
Several studies reported first disease presentations during pregnancy or within 12 months after delivery or pregnancy loss. Yet referral-based denominators prevented incidence estimates from being calculated cleanly. In plain terms, the studies identified cases, but they could not tell clinicians how often those first presentations truly occur in the broader population. That leaves a major gap in counseling for women who have never had a MOGAD attack but who are entering pregnancy with unexplained neurologic symptoms or a new postpartum syndrome.
Dal Bo et al. also reported reduced disease activity among 72 post-onset pregnancies. Even that larger experience fits the broader pattern: pregnancy did not appear to amplify relapse burden in the aggregate, and in several cohorts it was associated with less activity. Still, descriptive coherence is not the same as certainty. The review remains constrained by small samples, variable definitions, uneven follow-up, and the limits of observational referral cohorts.
What Neurologists Can Use Now, and What Still Cannot Be Assumed
For now, the review supports a cautious but more reassuring message for women with established MOGAD who are considering pregnancy. Gestation itself did not appear to be a high-relapse interval in most included cohorts, and the available ratios repeatedly leaned below 1. Postpartum counseling should stay more guarded, because the signal is less uniform and individual studies varied substantially. The safest interpretation is not that pregnancy eliminates relapse risk, but that the highest-risk assumptions historically applied to some autoimmune neurologic disorders may not map neatly onto MOGAD.
Clinical planning should still revolve around individualized relapse history, prior treatment exposure, and the timing of disease activity relative to conception and delivery. The review cannot answer whether one preventive strategy is superior to another, nor can it define a universal postpartum surveillance schedule. It also cannot resolve the risk of first presentation during the pregnancy-associated window because the denominators needed for incidence were not available. Those questions will require larger prospective cohorts with standardized relapse definitions, uniform postpartum follow-up, and better capture of pregnancies complicated by loss as well as live birth.